Reply:
Gisele N'Kontchou, Michel Beaugrand, Olivier Seror – 20 November 2009
High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy
Xiaofeng Fan, Qing Mao, Donghui Zhou, Yang Lu, Jianwei Xing, Yanjuan Xu, Stuart C. Ray, Adrian M. Di Bisceglie – 20 November 2009 – Differential response patterns to optimal antiviral therapy, peginterferon alpha plus ribavirin, are well documented in patients with chronic hepatitis C virus (HCV) infection. Among many factors that may affect therapeutic efficiency, HCV quasispecies (QS) characteristics have been a major focus of previous studies, yielding conflicting results.
Results of the IDEAL trial: “Mirror, mirror on the wall … Which's the fairest peg‐interferon of them all?”
Julian Schulze zur Wiesch, Ansgar W. Lohse – 20 November 2009
Reply:
Vincent Wai‐Sun Wong, Julien Vergniol, Henry Lik‐Yuen Chan, Victor de Lédinghen – 20 November 2009
Antiviral effects of the interferon‐induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein
Yasuhiro Itsui, Naoya Sakamoto, Sei Kakinuma, Mina Nakagawa, Yuko Sekine‐Osajima, Megumi Tasaka‐Fujita, Yuki Nishimura‐Sakurai, Gouki Suda, Yuko Karakama, Kako Mishima, Machi Yamamoto, Takako Watanabe, Mayumi Ueyama, Yusuke Funaoka, Seishin Azuma, Mamoru Watanabe – 20 November 2009 – Interferons (IFNs) and the interferon‐stimulated genes (ISGs) play a central role in antiviral responses against hepatitis C virus (HCV) infection.
The plasma lipidomic signature of nonalcoholic steatohepatitis
Puneet Puri, Michelle M. Wiest, Onpan Cheung, Faridoddin Mirshahi, Carol Sargeant, Hae‐Ki Min, Melissa J. Contos, Richard K. Sterling, Michael Fuchs, Huiping Zhou, Steven M. Watkins, Arun J. Sanyal – 20 November 2009 – Specific alterations in hepatic lipid composition characterize the spectrum of nonalcoholic fatty liver disease (NAFLD), which extends from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). However, the plasma lipidome of NAFLD and whether NASH has a distinct plasma lipidomic signature are unknown.
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients
Simone Susser, Christoph Welsch, Yalan Wang, Markus Zettler, Francisco S. Domingues, Ursula Karey, Eric Hughes, Robert Ralston, Xiao Tong, Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin – 20 November 2009 – Boceprevir is a hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor that is currently being evaluated in combination with peginterferon alfa‐2b and ribavirin in phase 3 studies. The clinical resistance profile of boceprevir is not characterized in detail so far. The NS3 protease domain of viral RNA was cloned from HCV genotype 1–infected patients (n = 22).
What is the relationship among microRNA‐181, epithelial cell‐adhesion molecule (EpCAM) and β‐catenin in hepatic cancer stem cells
Ji‐Peng Li, Jian‐Yong Zheng, Jian‐Jun Du, Rui Zhang, An‐Gang Yang – 20 November 2009
Reduced expression of ATP7B affected by Wilson disease–causing mutations is rescued by pharmacological folding chaperones 4‐phenylbutyrate and curcumin
Peter V. E. van den Berghe, Janneke M. Stapelbroek, Elmar Krieger, Prim de Bie, Stan F. J. van de Graaf, Reinoud E. A. de Groot, Ellen van Beurden, Ellen Spijker, Roderick H. J. Houwen, Ruud Berger, Leo W. J. Klomp – 20 November 2009 – Wilson disease (WD) is an autosomal recessive copper overload disorder of the liver and basal ganglia. WD is caused by mutations in the gene encoding ATP7B, a protein localized to the trans‐Golgi network that primarily facilitates hepatic copper excretion.